SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
Derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare, SOPHiA GENETICS's AI Factories offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data — including genomics, imaging, and clinical data — and generate AI-powered insights to help optimize breast cancer outcomes. The companies will also collaborate on real-world evidence generation in Europe and North America to uncover key drivers of treatment efficacy, address critical knowledge gaps, and enhance clinical decision-making through deeper insights.
"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."
"At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development," said Jorge Reis-Filho, Chief AI and Data Scientist, AstraZeneca. "Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer."
This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
CCC Intelligent Solutions Announces Pricing of Secondary Offering of 30 Million Shares of Common Stock
CCC Intelligent Solutions Holdings Inc. (the 'Company') (NASDAQ: CCCS) today announced the pricing of the previously announced secondary offering of the Company's common stock (the 'Offering') by affiliates of Advent International, L.P. (the 'Selling Stockholders') at a price to the public of $9.89 per share. The Offering consists of 30,000,000 shares of the Company's common stock. The Offering is expected to close on or about August 7, 2025, subject to the satisfaction of customary closing conditions. The Offering consists entirely of shares of the Company's common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. Goldman Sachs & Co. LLC is acting as book running manager for the Offering. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-267793), which has been filed with the Securities and Exchange Commission ('SEC') and became effective on October 14, 2022. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus. You may get these documents for free, including the prospectus supplement, once available, by visiting EDGAR on the SEC website at Alternatively, copies of the prospectus supplement, once available, and the accompanying base prospectus may be obtained by contacting: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. ABOUT CCC INTELLIGENT SOLUTIONS CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS), is a leading SaaS platform provider for the multi-trillion-dollar insurance economy, creating intelligent experiences for insurers, repairers, automakers, part suppliers, and more. The CCC Intelligent Experience (IX) Cloud™ platform, powered by proven AI and an innovative event-based architecture, connects more than 35,000 businesses to power customized applications and platforms for optimal outcomes and personalized experiences that just work. Through purposeful innovation and the strength of its connections, CCC technologies empower the people and industry relied upon to keep lives moving forward when it matters most. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the Offering, including the expected closing of the Offering. Such differences may be material. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, closing of the Offering on the anticipated terms or at all; market conditions; and the satisfaction of customary closing conditions related to the Offering; and other risks and uncertainties, including those included under the header 'Risk Factors' in our Form 10-K filed with the SEC on February 25, 2025, which can be obtained, without charge, at the SEC's website ( The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Globe and Mail
33 minutes ago
- Globe and Mail
OraSure (OSUR) Q2 Revenue Falls 43%
Key Points OraSure Technologies (NASDAQ:OSUR) reported GAAP revenue of $31.2 million and a non-GAAP loss per share of $(0.19), both modestly better than analyst estimates (non-GAAP EPS, GAAP revenue). Headline revenue (GAAP) declined 43% year over year due to the expected drop in COVID-19 and related business, but Diagnostics revenues increased 3% year-over-year. Cash burn accelerated and losses widened as margin pressures persisted, but cash levels remain high and investments in innovation and product launches continued. These 10 stocks could mint the next wave of millionaires › OraSure Technologies (NASDAQ:OSUR), a diagnostics and sample collection device company, released its second quarter 2025 results on August 5, 2025. The earnings showed that GAAP revenue was $31.2 million, slightly above the $30.36 million GAAP Wall Street estimate. Non-GAAP earnings per share (EPS) stood at $(0.19), improving on the consensus estimate of $(0.21) (non-GAAP). However, this result reflected a sharp drop in GAAP revenue, which decreased 43% from the prior year and a significant swing to operating losses (GAAP). The quarter's performance was better than expected by analysts, with both non-GAAP EPS and GAAP revenue exceeding analyst estimates, but overall financials remained pressured as the company continues to transition beyond pandemic-driven revenue peaks and adapts to a shifting funding and customer landscape. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $(0.19) $(0.21) $0.08 NM Revenue (GAAP) $31.2 million $30.36 million $54.3 million (43 %) Core Business Revenue $30.8 million $32.3 million -5 % Gross Margin (Non-GAAP) 43.2 % 47.4 % N/A Operating (Loss) Income (Non-GAAP) $(13.2) million $3.3 million NM Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Understanding OraSure Technologies' Business and Strategic Focus OraSure Technologies is known for developing and supplying rapid diagnostic tests and sample collection devices. Its portfolio includes self-tests for infectious diseases—such as the OraQuick® In-Home HIV test, the only U.S. over-the-counter oral HIV self-test—as well as tools for consumer genomics, blood and urine sample collection, and laboratory research. The company's recent focus revolves around innovation, expanding its diagnostic platform, and navigating regulatory requirements. It is investing in new products, such as molecular diagnostics for sexually transmitted infections, following its acquisition of Sherlock Biosciences. Core business success factors now include bringing new tests to market, differentiating its technology, and diversifying the customer base while efficiently managing manufacturing and supply chain transitions into its Pennsylvania facilities. Quarter Highlights: Financial and Operational Developments During the quarter, the company reported a sharp fall in overall revenue (GAAP) compared with the prior year, dropping by 43%. This headline decline mostly reflected the loss of COVID-19–related sales, which fell to near zero as pandemic-driven demand ended. At the same time, revenue from risk assessment testing and molecular services, both of which the company has now exited, slowed to minimal levels. Looking closer at its segments, the core diagnostics portfolio saw an increase in revenue of 3%, totaling $19.2 million. This category includes test kits for infectious disease and other clinical applications. However, sample management solutions—devices and kits used by researchers and genomics companies—fell 22% to $9.9 million (GAAP). The primary driver here was a steep reduction in orders from a single consumer genomics customer, which management flagged as a major concentration risk. Excluding this impact, growth was seen across the broader customer base in this segment. Margins were squeezed throughout the business compared to the prior year period. Gross margin (GAAP) dropped compared to the prior year as the mix of revenue shifted away from higher-margin COVID-19 products and international markets contributed a larger share. Operating income swung to a loss, with the non-GAAP figure at $(13.2) million versus a profit a year ago. Higher research and development (R&D) expenses—up 73% compared to the prior year—fueled by investments in new product development and clinical trials, also weighed on profitability. General and administrative spending climbed compared to the prior year, further reflecting the ongoing restructuring and launch investments. One-time and nonrecurring items were present, notably costs associated with restructuring and exit from certain segments. Non-GAAP results excluded these items. Meanwhile, the company began executing a $40 million share repurchase plan, spending $5 million to buy back 1.8 million shares. Cash and liquidity drew attention, with $234.6 million in cash and equivalents at quarter-end, but negative operating cash flow (GAAP) of $30 million for the first half of 2025. Management continued to highlight 'prudent capital allocation' to maintain investment in key growth programs, while operational efficiency initiatives—like insourcing U.S. manufacturing—are expected to drive improvement over the medium term. Product innovation and launches featured prominently. The company introduced HEMAcollect PROTEIN, a new blood collection device designed to stabilize proteins for research, and advanced Sherlock's molecular diagnostics platform with a new test for chlamydia and gonorrhea moving toward FDA submission. Key agreements with GeneDx and new product launches in sample collection for saliva and urine (like ORAcollect and Colli-Pee devices) remained on track, supporting plans for future portfolio expansion and regulatory clearance in multiple regions. Looking Ahead: Guidance and What to Watch Management's outlook signals ongoing revenue pressure, with projected GAAP sales in a range of $27 million to $30 million. No revenue bounce for COVID-19 testing was expected. Instead, it indicated that gross margin (GAAP) may stay flat or improve slightly in the second half of 2025 as production efficiencies and higher volumes emerge. Investors should watch for the pace of diversification in the customer base, progress in bringing new diagnostic products to market, and The end of the CDC's Together Take Me Home HIV testing initiative, which is expected to bring in approximately $4 million in revenue before the program ends at the close of Q3 2025, is set to weigh on future quarters. Continued cash burn and dependence on public health and consumer genomics funding add risk. Management remains focused on executing its innovation and portfolio strategy, but near-term visibility is limited. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025
Toronto Star
3 hours ago
- Toronto Star
Aura Declares Dividend of US$0.33 Per Share and US$0.11 Per BDR Based on Q2 2025 Results, Resulting in a Dividend Yield of 7.4% in the LTM
ROAD TOWN, British Virgin Islands, Aug. 05, 2025 (GLOBE NEWSWIRE) — Aura Minerals Inc. (Nasdaq: AUGO) (TSX: ORA) (B3: AURA33) ('Aura' or the 'Company') announced today that the Company's Board of Directors (the 'Board') has declared and approved the payment of a dividend (the 'Dividend') of US$0.33 per common share (approximately US$ 27.32 million in total). This payment is above the minimum foreseen in the Company's Dividend Policy (the 'Dividend Policy'). Under the Dividend Policy, the Company may determine quarterly cash dividends in an aggregate amount equal to 20% of its reported Adjusted EBITDA3 for the relevant three months, less sustaining capital expenditures and exploration capital expenditures for the same period. The Dividend will be paid in US dollars on August 26, 2025, to shareholders of record as of the close of business on August 18, 2025 ('Record Date').
